A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
The DNA damage response kinase ATR may be a useful cancer therapeutic target. ATR inhibition synergizes with loss of ERCC1, ATM, XRCC1 and DNA damaging chemotherapy agents. Clinical trials have begun using ATR inhibitors in combination with cisplatin. Here we report the first synthetic lethality screen with a combination treatment of an ATR inhibitor (ATRi) and cisplatin. Combination treatment with ATRi/cisplatin is synthetically lethal with loss of the TLS polymerase ζ and 53BP1. Other DNA repair pathways including homologous recombination and mismatch repair do not exhibit synthetic lethal interactions with ATRi/cisplatin, even though loss of some of these repair pathways sensitizes cells to cisplatin as a single-agent. We also report that ATRi strongly synergizes with PARP inhibition, even in homologous recombination-proficient backgrounds. Lastly, ATR inhibitors were able to resensitize cisplatin-resistant cell lines to cisplatin. These data provide a comprehensive analysis of DNA repair pathways that exhibit synthetic lethality with ATR inhibitors when combined with cisplatin chemotherapy, and will help guide patient selection strategies as ATR inhibitors progress into the cancer clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig 3 siRNA screen identifies synthetic lethal interactions with cisplatin and ATR inhibitor treatment. (A) Schematic of the siRNA screen. U2OS cells were transfected with siRNAs and then either left untreated or treated with 1μM ATRi, 0.5μM cisplatin, or ATRi and cisplatin. Cell viability was measured with alamar blue. (B) Viability of the non-targeting (NT) and ATR siRNA controls using the screen conditions. The values represent the mean ± SD of the three independent replicates of the screen. (C-E) The robust z-scores of treated compared with untreated cell viability were determined for each siRNA in the library for ATRi (C), cisplatin (D), and ATRi and cisplatin (E). The red circles represent the 8 unique siRNAs targeting ATR and ATRIP present in the library and the red line indicates a robust z score of -1.3. (F) Summary of the overlap of synthetic lethal relationships with ATRi, cisplatin, or ATRi and cisplatin. (G) Complete list of genes that exhibit a synthetic lethal relationship with ATRi, cisplatin, or ATRi and cisplatin. Genes with 2 or more siRNAs with robust z-scores of less than -1.3 are considered as synthetic lethal. The ATRi single-agent screen was previously published and included for comparison to the other drug treatments [18].](https://figures.cochat.ai/paper-figures/7ad76d20db1144d5b250ea00de8c7482/a-synthetic-lethal-screen-identifies-dna-repair-pathways-that-sensitize-cancer-figure-3.jpg)






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In a clinical context, this increase could lead to an inflammatory response and additional tissue damage, which contrasts with the less inflammatory (and more controlled) apoptosis [38, 39, 40].”
From Synergistic Potential of Argentatins A and B to Improve 5‐Fluorouracil Cytotoxicity in Colorectal Cancer Cell Models (2024) · cites this paper as [40]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 2×
“REV3 is also located within a fragile site deleted in several types of human leukemias and solid tumors [50], and 7% of B cell lymphomas in the TCGA data set have homozygous deletions in REV3 [49] making the synthetic lethal relationship with ATRi/cisplatin potentially useful clinically.”
BackgroundTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192 · cited 1×
“The PARP inhibitor BMN673 is 100-fold more potent at trapping PARP-DNA complexes than Olaparib or Veliparib [52] and functions by potently trapping PARP-DNA complexes, which are likely repaired by HR during DNA replication [26, 34].”
BackgroundActivation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009
ATR: an essential regulator of genome integrity
Cimprich, K. A., & Cortez, D. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2450 · Cited by 1,798 · cited 2×
“The DNA damage response kinase ATR (ATM- and Rad3-related) coordinates many of the cellular responses to DNA damage ATR is necessary to stabilize stalled replication forks and allow fork restart after damage [9].”
BackgroundSelf-citation53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
Bunting, S. F., Callén, E., Wong, N., Chen, H.-T., Polato, F., Gunn, A., Bothmer, A., Feldhahn, N., Fernandez-Capetillo, O., Cao, L., et al. (2010) · Cell · doi:10.1016/j.cell.2010.03.012 · Cited by 1,671
The search for synergy: a critical review from a response surface perspective.
Greco, W. R., Bravo, G., & Parsons, J. C. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06847-4 · Cited by 1,434 · cited 1×
“Isobologram analysis was performed as described [29, 30].”
Schlacher, K., Christ, N., Siaud, N., Egashira, A., Wu, H., & Jasin, M. (2011) · Cell · doi:10.1016/j.cell.2011.03.041 · Cited by 1,255 · cited 1×
“The following cell lines were previously described: BRCA2 defective and complemented VC8 cells [23], HCT-116 + chromosome 3 [24], hec59, and hec59 + chromosome 2 [25].”
MethodFong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010
Bouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1831 · Cited by 1,001 · cited 2×
“53BP1 loss in breast cancer correlates with TNBC status, loss of BRCA in hormone receptor positive breast cancer, and is associated with decreased overall survival [43, 51].”
BackgroundGenome instability: a mechanistic view of its causes and consequences
Aguilera, A., & Gómez-González, B. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2268 · Cited by 804 · cited 1×
“In the absence of ATR, stalled replication forks collapse into double strand breaks, which can lead to genomic rearrangements or cell death [10, 11].”
BackgroundMaintaining genome stability at the replication fork
Branzei, D., & Foiani, M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2852 · Cited by 786 · cited 1×
“In the absence of ATR, stalled replication forks collapse into double strand breaks, which can lead to genomic rearrangements or cell death [10, 11].”
BackgroundTriple-Negative Breast Cancer: An Unmet Medical Need
Hudis, C. A., & Gianni, L. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-01 · Cited by 780
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J., Takeda, S., Morris, J., Teicher, B., Doroshow, J. H., & Pommier, Y. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 756 · cited 2×
“The PARP inhibitor BMN673 is 100-fold more potent at trapping PARP-DNA complexes than Olaparib or Veliparib [52] and functions by potently trapping PARP-DNA complexes, which are likely repaired by HR during DNA replication [26, 34].”
BackgroundLukas, C., Savic, V., Bekker-Jensen, S., Doil, C., Neumann, B., Sølvhøj Pedersen, R., Grøfte, M., Chan, K. L., Hickson, I. D., Bartek, J., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2201 · Cited by 667 · cited 2×
“53BP1 is also required to protect chromosomal fragile sites and other under-replicated regions during mitosis for eventual repair in the subsequent G1 [44, 45].”
BackgroundSelective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
Reaper, P. M., Griffiths, M. R., Long, J. M., Charrier, J.-D., MacCormick, S., Charlton, P. A., Golec, J. M. C., & Pollard, J. R. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.573 · Cited by 633 · cited 4×
“These interactions were previously identified using null and complemented cell lines as well as small molecule inhibitors [19, 20].”
BackgroundMethodInfluentialA three-dimensional model to analyze drug-drug interactions
Prichard, M. N., & Shipman, C. (1990) · Antiviral Research · doi:10.1016/0166-3542(90)90001-n · Cited by 544 · cited 2×
“Synergy Analysis Bliss independence log synergy volumes (μM(2)%) were calculated with using MacSynergy II and reported at the 95% confidence interval for one replicate (n = 3) [28].”
BackgroundMethodPatel, A. G., Sarkaria, J. N., & Kaufmann, S. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013715108 · Cited by 541
DNA damage signalling guards against activated oncogenes and tumour progression
Bartek, J., Bartkova, J., & Lukas, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210881 · Cited by 521
Koi, M., Umar, A., Chauhan, D. P., Cherian, S. P., Carethers, J. M., Kunkel, T. A., & Boland, C. R. (1994) · PubMed · Cited by 515
Shen, Y., Rehman, F. L., Feng, Y., Boshuizen, J., Bajrami, I., Elliott, R., Wang, B., Lord, C. J., Post, L. E., & Ashworth, A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1391 · Cited by 479 · cited 4×
“The PARP inhibitor BMN673 is 100-fold more potent at trapping PARP-DNA complexes than Olaparib or Veliparib [52] and functions by potently trapping PARP-DNA complexes, which are likely repaired by HR during DNA replication [26, 34].”
BackgroundMethodInfluentialToledo, L. I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S., Oyarzabal, J., Pastor, J., Bischoff, J. R., & Fernandez-Capetillo, O. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2076 · Cited by 465
ANTAGONISTS OF NUCLEIC ACID DERIVATIVES
Elion, G. B., Singer, S., & Hitchings, G. H. (1954) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)65573-5 · Cited by 427
ATR phosphorylates SMARCAL1 to prevent replication fork collapse
Couch, F. B., Bansbach, C. E., Driscoll, R., Luzwick, J. W., Glick, G. G., Bétous, R., Carroll, C. M., Jung, S. Y., Qin, J., Cimprich, K. A., et al. (2013) · Genes & Development · doi:10.1101/gad.214080.113 · Cited by 406 · cited 2×
“Performed and quantified as previously described [27].”
MethodSelf-citationFokas, E., Prevo, R., Pollard, J. R., Reaper, P. M., Charlton, P. A., Cornelissen, B., Vallis, K. A., Hammond, E. M., Olcina, M. M., Gillies McKenna, W., et al. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.181 · Cited by 369 · cited 1×
“ATR inhibition has shown efficacy in a mouse model of pancreatic cancer in combination with gemcitabine, and in patient-derived lung tumor xenografts in combination with cisplatin [16, 22].”
BackgroundReplication stress induces 53BP1-containing OPT domains in G1 cells
Harrigan, J. A., Belotserkovskaya, R., Coates, J., Dimitrova, D. S., Polo, S. E., Bradshaw, C. R., Fraser, P., & Jackson, S. P. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201011083 · Cited by 343 · cited 2×
“53BP1 is also required to protect chromosomal fragile sites and other under-replicated regions during mitosis for eventual repair in the subsequent G1 [44, 45].”
BackgroundA synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
Turner, N. C., Lord, C. J., Iorns, E., Brough, R., Swift, S., Elliott, R., Rayter, S., Tutt, A. N., & Ashworth, A. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.61 · Cited by 322 · cited 2×
“However, ATR was identified as the third highest scoring gene in a screen looking for synthetic lethal interactions with PARP inhibition [35] and ATR inhibition sensitized ovarian cancer cells to the PARP inhibitor Veliparib [36].”
BackgroundCharrier, J.-D., Durrant, S. J., Golec, J. M. C., Kay, D. P., Knegtel, R. M. A., MacCormick, S., Mortimore, M., O'Donnell, M. E., Pinder, J. L., Reaper, P. M., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101488z · Cited by 255 · cited 3×
“Selective ATR inhibitors have been described by Vertex Pharmaceuticals [15, 16] and AstraZeneca [17] and are currently in phase I clinical trials in combination with DNA damaging chemotherapy drugs or radiation therapy.”
BackgroundANTAGONISTS OF NUCLEIC ACID DERIVATIVES
Hitchings, G. H., Falco, E. A., Vanderwerff, H., Russell, P. B., & Elion, G. B. (1952) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)44808-9 · Cited by 235
Foote, K. M., Blades, K., Cronin, A., Fillery, S., Guichard, S. S., Hassall, L., Hickson, I., Jacq, X., Jewsbury, P. J., McGuire, T. M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301859s · Cited by 214 · cited 1×
“Selective ATR inhibitors have been described by Vertex Pharmaceuticals [15, 16] and AstraZeneca [17] and are currently in phase I clinical trials in combination with DNA damaging chemotherapy drugs or radiation therapy.”
BackgroundATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status
Huntoon, C. J., Flatten, K. S., Wahner Hendrickson, A. E., Huehls, A. M., Sutor, S. L., Kaufmann, S. H., & Karnitz, L. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0110 · Cited by 202 · cited 3×
“The PARP inhibitor BMN673 is 100-fold more potent at trapping PARP-DNA complexes than Olaparib or Veliparib [52] and functions by potently trapping PARP-DNA complexes, which are likely repaired by HR during DNA replication [26, 34].”
BackgroundPotentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
Hall, A. B., Newsome, D., Wang, Y., Boucher, D. M., Eustace, B., Gu, Y., Hare, B., Johnson, M. A., Li, H., Milton, S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2158 · Cited by 199 · cited 2×
“Selective ATR inhibitors have been described by Vertex Pharmaceuticals [15, 16] and AstraZeneca [17] and are currently in phase I clinical trials in combination with DNA damaging chemotherapy drugs or radiation therapy.”
BackgroundUmar, A., Koi, M., Risinger, J. I., Glaab, W. E., Tindall, K. R., Kolodner, R. D., Boland, C. R., Barrett, J. C., & Kunkel, T. A. (1997) · PubMed · Cited by 193
Management of breast cancer with targeted agents: importance of heterogenicity
Di Cosimo, S., & Baselga, J. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.234 · Cited by 161
Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer
Anders, C. K., Winer, E. P., Ford, J. M., Dent, R., Silver, D. P., Sledge, G. W., & Carey, L. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0939 · Cited by 154
ATR Pathway Inhibition Is Synthetically Lethal in Cancer Cells with ERCC1 Deficiency
Mohni, K. N., Kavanaugh, G. M., & Cortez, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3229 · Cited by 150 · cited 13×
“Inactivation of the ERCC1-XPF endonuclease as well as loss of known ATR pathway proteins and DNA replication proteins strongly sensitized cells to ATR inhibition [18].”
BackgroundMethodResultSelf-citationThe potential of exploiting DNA-repair defects for optimizing lung cancer treatment
Postel-Vinay, S. C., Vanhecke, E., Olaussen, K. A., Lord, C. J., Ashworth, A., & Soria, J. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.3 · Cited by 132
Wang, H., Wang, H., Powell, S. N., Iliakis, G., & Wang, Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1289 · Cited by 130 · cited 1×
“The lack of synthetic lethality may be because inhibition of ATR reduces the efficiency of HR so no further synergy is observed in HR-deficient backgrounds [31].”
BackgroundSystemic therapy of advanced non-small cell lung cancer: Major-developments of the last 5-years
Čufer, T., Ovčariček, T., & O'Brien, M. E. R. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.021 · Cited by 107 · cited 1×
“NSCLC patients receive platinum as a first-line drug and typically survive less than one year [8].”
BackgroundMorelli, M. C., Karayianni, E., Magnanini, C., Mungall, A. J. J., Thorland, E. C., Negrini, M., Smith, D. I., & Barbanti‐Brodano, G. (2002) · Oncogene · doi:10.1038/sj.onc.1205573 · Cited by 85 · cited 1×
“REV3 is also located within a fragile site deleted in several types of human leukemias and solid tumors [50], and 7% of B cell lymphomas in the TCGA data set have homozygous deletions in REV3 [49] making the synthetic lethal relationship with ATRi/cisplatin potentially useful clinically.”
BackgroundSultana, R., Abdel-Fatah, T., Perry, C., Moseley, P., Albarakti, N., Mohan, V., Seedhouse, C., Chan, S., & Madhusudan, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057098 · Cited by 84 · cited 1×
“These interactions were previously identified using null and complemented cell lines as well as small molecule inhibitors [19, 20].”
BackgroundIncreased PARP-1 Association with DNA in Alkylation Damaged, PARP-Inhibited Mouse Fibroblasts
Kedar, P. S., Stefanick, D. F., Horton, J. K., & Wilson, S. H. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0477 · Cited by 82
Bhat, A., Andersen, P. L., Qin, Z., & Xiao, W. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks1442 · Cited by 80 · cited 1×
“In addition to its role in cisplatin resistance, REV3 is also required for maintaining viability after replication fork stalling and for preventing expression of common fragile sites [46, 47].”
BackgroundInhibition of REV3 Expression Induces Persistent DNA Damage and Growth Arrest in Cancer Cells
Knobel, P. A., Kotov, I. N., Felley‐Bosco, E., Stahel, R. A., & Marti, T. M. (2011) · Neoplasia · doi:10.1593/neo.11828 · Cited by 66 · cited 4×
“Loss of REV3 also causes persistent DNA damage and an increase in γH2AX [48].”
BackgroundInfluentialHorton, J. K., Stefanick, D. F., Naron, J. M., Kedar, P. S., & Wilson, S. H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413841200 · Cited by 63
Translesion DNA synthesis in the context of cancer research
Knobel, P. A., & Marti, T. M. (2011) · Cancer Cell International · doi:10.1186/1475-2867-11-39 · Cited by 60 · cited 2×
“Pol z is viewed as a master regulator in TLS, as Pol z and REV1 are required to complete repair initiated by several other TLS polymerases [40].”
BackgroundHeacock, M. L., Stefanick, D. F., Horton, J. K., & Wilson, S. H. (2010) · DNA repair · doi:10.1016/j.dnarep.2010.05.007 · Cited by 59
Güler, G., Himmetoğlu, Ç., Jiménez, R. E., Geyer, S. M., Wang, W. P., Costinean, S., Pilarski, R., Morrison, C., Süren, D., Liu, J., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1248-6 · Cited by 55
Neboori, H. J., Haffty, B. G., Wu, H., Yang, Q., Aly, A., Goyal, S., Schiff, D. S., Moran, M. S., Golhar, R., Chen, C., et al. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.01.089 · Cited by 31 · cited 2×
“53BP1 loss in breast cancer correlates with TNBC status, loss of BRCA in hormone receptor positive breast cancer, and is associated with decreased overall survival [43, 51].”
BackgroundNovel Treatment Approaches for Triple-Negative Breast Cancer
Telli, M. L., & Ford, J. M. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.s.003 · Cited by 25
Whole genome RNAi screens reveal a critical role of REV3 in coping with replication stress
Kotov, I. N., Olst, E. S., Knobel, P. A., van der Meulen‐Muileman, I. H., Felley‐Bosco, E., van Beusechem, V. W., Smit, E. F., Stahel, R. A., & Marti, T. M. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.008 · Cited by 14 · cited 1×
“In addition to its role in cisplatin resistance, REV3 is also required for maintaining viability after replication fork stalling and for preventing expression of common fragile sites [46, 47].”
Background
Cited by
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Yazinski, S. A., Comaills, V., Buisson, R., Genois, M.-M., Nguyen, H. D., Ho, C. K., Todorova Kwan, T., Morris, R., Lauffer, S., Nussenzweig, A., et al. (2017) · Genes & Development · doi:10.1101/gad.290957.116 · Cited by 395
ATR/CHK1 inhibitors and cancer therapy
Qiu, Z., Oleinick, N. L., & Zhang, J. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.09.043 · Cited by 370
The plasticity of DNA replication forks in response to clinically relevant genotoxic stress
Berti, M., Cortez, D., & Lopes, M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0257-5 · Cited by 329
Self-citationLecona, E., & Fernandez-Capetillo, O. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0034-3 · Cited by 325
Metadata
- Authors
- Mohni, K. N., Thompson, P. S., Luzwick, J. W., Glick, G. G., Pendleton, C. S., Lehmann, B. D., Pietenpol, J. A., & Cortez, D.
- Affiliations
- Vanderbilt University (US)
- Corresponding author
- Cortez, David
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-05-12
- Volume
- 10
- Issue
- 5
- Pages
- e0125482
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4428765
- OpenAlex
- W1591550632
- Cited by
- 108
- References
- 54
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 5 · 2023: 10 · 2022: 8 · 2021: 8 · 2020: 11 · 2019: 12 · 2018: 19 · 2017: 18 · 2016: 9 · 2015: 3
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Breast Cancer Research Foundation (PDF14302198)
- National Institutes of Health (CA95131)
- National Cancer Institute (R01CA102729, T32CA093240, CA95131, CA 102792, R01CA102792, T32CA009582)
- National Institute of General Medical Sciences (T32GM007347)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- ATR inhibitors, cisplatin, synthetic lethality, DNA repair pathways, DNA damage response, 53BP1, homologous recombination, DNA mismatch repair, PARP inhibition, cisplatin resistance, combination therapy, cancer therapeutics
- MeSH terms
- Tumor Suppressor p53-Binding Protein 1, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Cell Survival, Cisplatin, DNA-Directed DNA Polymerase, DNA Repair, Drug Synergism, Humans, Pyrazines, Sulfones, Gene Library, Drug Resistance, Neoplasm, RNA, Small Interfering, HCT116 Cells, Cell Line, Tumor, Intracellular Signaling Peptides and Proteins, Ataxia Telangiectasia Mutated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.